Booth Bruce sold $1.1M of KYMR
Booth Bruce sold 11,741 shares of Kymera Therapeutics, Inc. (KYMR) at $89.98 ($1.06M total) on 2026-06-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market sale of 11,741 shares at $89.98/share on 2026-06-17, with holdings after the trade reported as 0 shares.
Market read
Traders may monitor KYMR for follow-on insider activity, but the filing alone does not change fundamentals.
What to watch
The filing does not reveal reasons for the sale, and the director’s role (and any other holdings) beyond this direct position is not provided.
Background
This is an SEC Form 4 insider transaction for Kymera Therapeutics, Inc. (KYMR).
Ticker impact
Kymera Therapeutics director Booth Bruce sold 11,741 shares in an open-market transaction for about $1.06M, leaving 0 shares.
Likely limited near-term impact; any reaction would be sentiment-driven rather than based on new company fundamentals.
The filing is a routine Form 4 with a pre-arranged 10b5-1 plan and the director ends with 0 shares, but no new operational/financial information is disclosed.
Market effects
Minimal; this is company-specific insider activity with no sector-wide signal.
None.
None.
Counterpoint
Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider sale by a director.
- insiderBooth Bruce
Director who sold 11,741 shares under a 10b5-1 plan.
